Evofem Biosciences GAAP EPS of -$0.03, revenue of $7.1M

Stock Information for Evofem Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Evofem Biosciences Inc.

Evofem's PHEXXI Submitted for Marketing Approval in United Arab Emirates by Pharma 1 Drug Store
Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting
Evofem Signs SOLOSEC License Agreement for Middle East with Pharma 1
Evofem Reports First Quarter 2025 Financial Results and Provides Business Update
Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream
Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates
Evofem Biosciences to Present at Emerging Growth Conference
Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.